Dogwood Therapeutics (NASDAQ:DWTX) Posts Earnings Results, Beats Expectations By $0.02 EPS

Dogwood Therapeutics (NASDAQ:DWTX) posted its quarterly earnings results on Thursday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02, FiscalAI reports. The business had revenue of $0.10 million during the quarter.

Dogwood Therapeutics Stock Up 23.1%

Shares of DWTX traded up $0.24 during mid-day trading on Friday, reaching $1.28. The company had a trading volume of 171,530 shares, compared to its average volume of 72,479. Dogwood Therapeutics has a 52-week low of $0.90 and a 52-week high of $7.04. The stock has a 50 day moving average of $1.54 and a two-hundred day moving average of $1.95.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Thursday, October 22nd. HC Wainwright reissued a “buy” rating on shares of Dogwood Therapeutics in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.